Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 28, 2017; 23(32): 5836-5848
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5836
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5836
Ref. | Country | Study design | Ocular exam sample | Ocular manifestationfrequency | Comment |
Karmiris et al[56] (2016) | Greece | Prospective cohort | 1860 (1001 CD; 859 UC) | 55 (3%) | Ocular EIMs represented the third most frequent group of EIM in the study |
(45 CD; 10 UC): 31 Anterior uveitis (25 CD; 6 UC); 16 Episcleritis (16 CD); 7 Posterior uveitis (3 DC; 4 UC); 1 Central serous retinopathy (CD) | All patients with episcleritis suffered from CD. There were patients with anterior and posterior uveitis | ||||
Manser et al[57] (2016) | Switzerland | 140 UC patients with EIM or complications | 22 (15.7%) Uveitis | Investigated prevalence of uveitis in patients with UC | |
Bandyopadhyay et al[27] (2015) | India | 120 (62 CD; 58 UC) | 16 (13%)(8 CD; 8 UC): 7 Uveitis (7 CD); 9 Episcleritis (1 CD; 8 UC) | Authors describe two cases of scleritis (2 CD) and one of endophthalmitis (CD) that were not accounted as ocular manifestations. Authors consider a selection bias, as most participants had severe intestinal disease | |
Isene et al[58] (2015) | Europe (Norway, Denmark, Netherlands, Spain, Italy, Greece, and Israel) | Prospective cohort | 1145 (364 CD; 781 UC) | 12 (1.0%)10 (0.9%) Anterior uveitis; 2 (0.2%) Episcleritis | Authors concluded that familial IBD does not predict increased risk of immune-mediated EIM, as smoking does not seem to influence the risk |
Zippi et al[28] (2014) | Italy | Retrospective | 811 (216 CD; 595 UC) | 26 Uveitis (3.2%)(16 CD; 10 UC) | It is not informed if other ocular manifestations have been investigated in addition to uveitis. |
Cloché et al[59] (2013) | France | 74 IBD (no underlying disease specification) | 1 (1.4%): Scleritis | A large number of patients were receiving biological agents, approximately 50%, that may treat IBD and prevent ocular inflammation. Authors do not define the underlying IBD of the scleritis patient | |
Vavricka et al[22] (2011) | Switzerland | Prospective Cohort | 950 (580 CD; 370 UC) | 50 (5.3%)(36 CD; 14 UC): 50 Uveitis | Only uveitis was considered ocular EIM, and it was associated to active CD, but no relation was found to UC activity |
Cury et al[60] (2010) | Brazil | 88 (48 CD; 40 UC) | 7 (6.25%)(no underlying disease specification): 1 Conjunctivitis; 3 Blepharitis; 1 Episcleritis; 2 Uveitis; 2 Cataracts | The study used a control group of 24. Considered also unspecific ocular abnormalities, as cataract and blepharitis | |
Felekis et al[61] (2009) | Greece | Prospective cohort | 60 (23 CD; 37 UC) | 26 (43%)(12 CD; 14 UC): 13 Dry eye; 8 Glucocorticoid-induced cataract; 3 Iridociclitis; 3 Retinal pigment epithelium disturbances; 2 Episcleritis; 2 Serous retinal detachment; 1 Conjunctivitis; 1 Choroiditis; 1 Vasculitis; 1 Optic neuritis | The study used a control group of 276. Authors conclude that ocular manifestations occur in UC patients as frequently as in CD patients; however, the results of the statistical analysis are not mentioned for any of the study variables |
Lanna et al[25] (2008) | Brazil | 96 (59 CD; 37 UC) | 6 (6.2%)(4 CD; 2 UC): 4 Uveitis (2 bilateral; 2 CD; 2 UC); 1 Scleritis (CD); 1 Episcleritis (CD) | It was not possible to analyze the association between the HLA-B27 and ocular abnormalities because only 3 of the 6 patients had been tested for HLA-B27; all of them were negative for this antigen | |
Yilmaz et al[35] (2007) | Turkey | Prospective cohort | 116 (20 CD; 96 UC) | 28 (24.13%)(12 CD; 22 UC): 10 Conjunctivitis; 8 Blepharitis; 6 Uveitis; 6 Cataracts; 4 Episcleritis | Study considered unspecific ocular abnormalities, as cataract and blepharitis, which are very frequent in the general population |
Mendoza et al[29] (2005) | Spain | Prospective cohort | 566 (295 CD; 271 UC) | 13 (2.3%)(6 CD; 7 UC): 8 Uveitis (2 CD; 6 UC); 5 Episcleritis (4 CD; 1 UC) | In 2 patients the ophthalmologic clinical presentation preceded the diagnosis of IBD, but its frequency is probably undervalued considering the high prevalence of asymptomatic uveitis |
Ricart et al[47] (2004) | United States | 243 IBD [47 familial IBD (25 CD; 22 UC); 196 sporadic IBD (114 CD; 82 UC)] | Familial IBD: 3 (2 CD; 1 UC)Sporadic IBD: 10 (7 CD; 3 UC)Authors don't specify which ocular EIM was found | Significant association between EIM and disease status (familial vs sporadic) was not detected. This suggests that susceptibility genes for the development of IBD and the susceptibility genes for the development of EIM are different | |
Lakatos et al[2] (2003) | Hungary | Prospective cohort | 873 (254 CD; 619 UC) | 28 (3.2%)(8 CD; 20 UC): 13 Conjunctivitis (4 CD; 9 UC), 10 Anterior uveitis (4 CD; 6 UC); 5 Scleritis (1 CD; 4 UC); 1 Orbital pseudotumor (female UC patient) | The prevalence was more frequent in women in both UC and CD. In UC more than half of the patients with ocular complication had pancolitis |
Christodoulou et al[62] (2002) | Greece | Retrospective | 248 (37 CD; 215 UC) | 4 (1.61%)(1 CD; 3 UC): 4 Iridocyclitis | Evaluated only iridocyclitis as ocular EIM |
SUN classification | Primary site of inflammation | Manifestation |
Anterior uveitis | Anterior chamber | Iritis, iridocyclitis, anterior cyclitis |
Intermediate uveitis | Vitreous | Pars planitis, posterior cyclitis, hyalitis |
Posterior uveitis | Retina or choroid | Focal, multifocal or diffuse choroiditis, chorioretinitis, retinochoroiditis, retinitis, neuroretinitis |
Panuveitis | Anterior chamber, vitreous, and retina or choroid |
Ref. | Country | Ocular impairment | IBD |
Hwang et al[89] (2001) | Canada | Dacryoadenitis | CD |
Mochizuki et al[90] (2010) | Japan | UC | |
Boukouvala et al[91] (2012) | United Kingdom | CD | |
Jakobiec et al[92] (2014) | United States | 2 CD | |
Ruiz Serrato et al[15] (2013) | Spain | Palpebral ptosis | CD |
Diaz-Valle et al[93] (2004) | Spain | Lid margin ulcers | CD |
Leibovitch et al[94] (2005) | Australia | Pyodermatitis-pyostomatitis vegetans of eyelids | UC |
Garrity et al[95] (2004) | United States | Orbital myositis | 2 CD |
Verma et al[96] (2013) | Canada | CD | |
Foroozan et al[97] (2003) | United States | Ocular miasthenia graves | UC |
Pham et al[31] (2011) | United States | Peripheral ulcerative keratitis | 3 CD |
Roszkowska et al[98] (2013) | Italy | Salzmann nodular corneal degeneration | CD |
Zullow et al[99] (2017) | United States | Central serous chorioretinopathy | UC |
Geyshis et al[100] (2013) | Israel | UC | |
Assadsangabi et al[101] (2010) | United Kingdom | CD | |
Ugarte et al[102] (2002) | United Kingdom | Serpiginous chorioretinopathy | CD |
Casalino et al[103] (2014) | Italy | Choroidal neovascularization | CD |
Thomas et al[104] (2014) | United States | CD | |
Unal et al[105] (2008) | Turkey | CD | |
Saatci et al[106] (2002) | Turkey | Retinal vasculitis | CD |
Larsson et al[107] (2000) | Sweden | Retinal vein occlusion | 1 CD, 1 UC |
Buchman et al[108] (2006) | United States | UC | |
Unal et al[105] (2008) | Turkey | CD | |
Yamane et al[109] (2007) | Brazil | CD | |
Vayalambrone et al[110] (2011) | United Kingdom | UC | |
Falavarjani et al[111] (2012) | Iran | Retinal artery occlusion | CD |
Abdul-Rahman et al[112] (2010) | New Zealand | CD | |
Saatci et al[106] (2002) | Turkey | CD | |
Siqueira et al[113] (2016) | Brazil | CD | |
Saatci et al[106] (2002) | Turkey | Retinal neovascularization | CD |
Fuentes-Páez et al[114] (2007) | Spain | Subretinal fibrosis and uveitis syndrome | UC |
Munk et al[115] (2016) | United States | Acute macular neuroretinopathy | UC |
McClelland et al[116] (2012) | United States | Optic perineuritis | CD |
Felekis et al[117] (2010) | Greece | Anterior ischemic optic neuropathy | CD |
Mason et al[118] (2002) | United States | Macular edema | CD |
De Franceschi et al[119] (2000) | Italy | Dystrophy of the retinal pigment epithelium | CD |
Villain et al[120] (2002) | France | Pseudotumor cerebri | CD |
- Citation: Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol 2017; 23(32): 5836-5848
- URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5836.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5836